Targeted therapy trial aims to keep endometrial cancer from returning

NCT ID NCT07022483

Recruiting now Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a newer, targeted drug called trastuzumab deruxtecan (T-DXd) works better than standard chemotherapy after surgery for certain types of endometrial cancer. It is for people whose cancer tests positive for a protein called HER2. The main goal is to see if the new treatment helps patients live longer without their cancer coming back.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Avera Medical Group Gynecologic Oncology Sioux Falls
RECRUITING

Sioux Falls, South Dakota, 57105, United States
Beijing Cancer Hospital
RECRUITING

Beijing, China
Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, China
Cancer Institute Hospital of JFCR
RECRUITING

Kōtoku, Japan
Fukushima Medical University Hospital
RECRUITING

Fukushima, Japan
Guangxi Medical University Affiliated Tumor Hospital
RECRUITING

Nanning, China
Gunma Prefectural Cancer Center
RECRUITING

Ota-shi, Japan
Hyogo Cancer Center
RECRUITING

Akashi-shi, Japan
Jiangxi Maternal and Child Health Hospital
RECRUITING

Nanchang, China
Keimyung University Dongsan Hospital
RECRUITING

Daegu, South Korea
Keio University Hospital
RECRUITING

Shinjuku-ku, Japan
Kurume University Hospital
RECRUITING

Kurume-shi, Japan
Linyi Cancer Hospital
RECRUITING

Linyi, China
Mie University Hospital
RECRUITING

Tsu, Japan
Mount Sinai Medical Center
RECRUITING

Miami Beach, Florida, 33140, United States
NHO Hokkaido Cancer Center
RECRUITING

Sapporo, Japan
NHO Kyushu Cancer Center
RECRUITING

Fukuoka, Japan
National Cheng Kung University Hospital
RECRUITING

Tainan, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, Taiwan
Niigata Cancer Center Hospital
RECRUITING

Niigata, Japan
Obstetrics and Gynecology Hospital Affiliated to Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
Okayama University Hospital
RECRUITING

Okayama, Japan
Saitama Medical University International Medical Center
RECRUITING

Hidaka-shi, Japan
Samsung Medical Center
RECRUITING

Seoul, South Korea
Seoul National University Hospital
RECRUITING

Seoul, South Korea
Shanghai First Maternity and Infant HospitalShanghai First Maternity and Infant Hospital
RECRUITING

Shanghai, China
Shanghai Tenth People's Hospital
RECRUITING

Shanghai, China
Taichung Veterans General Hospital
RECRUITING

Taichung, Taiwan
Taipei Veterans General Hospital
RECRUITING

Taipei, Taiwan
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, China
The First Hospital of Jilin University
RECRUITING

Changchun, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, China
Tohoku University Hospital
RECRUITING

Sendai, Japan
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
RECRUITING

Wuhan, China
Trials365 LLC
RECRUITING

Shreveport, Louisiana, 71103, United States
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING

Wuhan, China
West China Second University Hospital, Sichuan University
RECRUITING

Chengdu, China
Yamagata University Hospital
RECRUITING

Yamagata, Japan
Yantai Yuhuangding Hospital
RECRUITING

Yantai, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, China

Conditions

Explore the condition pages connected to this study.

ENDOMETRIAL CANCER